Pharma News

Aspect Biosystems secured C$79 million from Canada to support a multi-year cellular medicine project for endocrine and metabolic diseases.

SK biopharmaceuticals will present preclinical data on SKL35501 and SKL35502 at AACR 2026, highlighting its NTSR1-targeted theranostics strategy.

Teva received FDA approval for Ponlimsi, a Prolia biosimilar, while FDA and EMA accepted filings for its proposed Xolair biosimilar.

FDA granted full approval to Tecartus for adults with relapsed or refractory mantle cell lymphoma, expanding use beyond prior BTK inhibitor exposure.

Intelligent Bio Solutions completed a fingerprint-based codeine screen study, supporting a planned FDA 510(k) submission for U.S. clearance.

Adagene and Incyte will start a Phase 1 trial in 2026 testing muzastotug with INCA33890 in third-line MSS colorectal cancer patients.

India’s Department of Pharmaceuticals said AI is reshaping drug discovery, clinical development, regulation and post-market safety monitoring.

Biogen agreed to acquire Apellis for $5.6 billion, adding Syfovre and Empaveli and strengthening its rare disease and immunology pipeline.

Eli Lilly’s Foundayo won FDA approval as a GLP-1 weight loss pill that can be taken without food and water restrictions, expanding obesity treatment options.

A rare disease coalition urged the Trump administration to restore FDA clarity as leadership changes loom at the biologics review center.

FDA granted RMAT designation to CB-011 for relapsed or refractory multiple myeloma, supporting faster development and potential accelerated approval.

Voro Therapeutics will present new preclinical PrimeBody and VOR-101 data at AACR 2026 and AET Europe, highlighting tumor-activated biologics.